CTLA4[Biotinylated]:B7-2 Inhibitor Screening Assay Kit

Catalog #
72024
$1,075 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The CTLA4[Biotinylated]:B7-2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-2 interaction. The key to this kit is the high sensitivity of detection of biotin-labeled CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, B7-2 is coated on a 96-well plate. Next, CTLA4-biotin is incubated with B7-2 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

Synonyms
T-lymphocyte activation antigen CD86, B7.2, FUN-1, B70, BU63, CD86, Cytotoxic T-lymphocyte-associated protein 4, CD152, B72, activity assay kit, CTLA-4
Product Info
Storage and Usage
Citations
Assay Kit Format
Chemiluminescent
Supplied As
This kit comes in a convenient 96- well format, with biotin-labeled CTLA4 (CD152), purified B7-2 (CD86), streptavidin-labeled HRP, and assay buffer for 100 binding reactions
Format

Catalog
Number


Component


Amount


Storage

71152

CTLA4 (CD152), Fc fusion, Biotin-labeled

5 µg

-80°C







(Avoid
freeze/
thaw
cycles!)

71150

B7-2 (CD86), Fc fusion

10 µg

-80°C

79742

Streptavidin-HRP

15 µl

+4°C

79311

3x Immuno Buffer 1

50 ml

-20°C

Blocking Buffer

50 ml

+4°C

 

HRP chemiluminescent substrate A 
(transparent bottle)

6 ml

+4°C

 

 

HRP chemiluminescent substrate B 
(brown bottle)

6 ml

+4°C

79699

White 96-well microplate 

1

+4°C

UniProt #
CTLA4: P16410; B7-2: P16410
Background
B7-2 (CD86) signaling through CTLA4(CD152) has been shown to inhibit T cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host’s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer.
References
1. Ohtani, H., et al., Lab Invest. 1997; 77(3): 231-241.
2. Rovert, C., et al., N. Engl. J. Med. 2011; 364: 2517-25262.